Lindsey Rolfe - 01 Jun 2022 Form 4 Insider Report for Clovis Oncology, Inc.

Role
Officer
Signature
/s/ Lindsey Rolfe
Issuer symbol
N/A
Transactions as of
01 Jun 2022
Net transactions value
-$1,703
Form type
4
Filing time
03 Jun 2022, 16:15:40 UTC
Previous filing
03 May 2022
Next filing
10 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLVS Common Stock Options Exercise +5,062 +5% 105,666 01 Jun 2022 Direct F1
transaction CLVS Common Stock Sale $1,703 -2,650 -2.5% $0.6425* 103,016 02 Jun 2022 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLVS Restricted Stock Units Options Exercise $0 +5,062 +10% $0.000000 55,688 01 Jun 2022 Common Stock 5,062 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit represents the right to receive one share of Common Stock.
F2 Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person.
F3 This transaction was executed in multiple trades at prices ranging from $0.642368 to $0.645500. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4 On March 1, 2021, the reporting person was granted 81,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2022, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date

Remarks:

Chief Medical Officer and Executive Vice President of Clinical and Preclinical Development and Pharmacovigilance